Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

Similar articles for PubMed (Select 25072324)

1.

Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals.

Paterson RW, Bartlett JW, Blennow K, Fox NC; Alzheimer's Disease Neuroimaging Initiative, Shaw LM, Trojanowski JQ, Zetterberg H, Schott JM.

Transl Psychiatry. 2014 Jul 29;4:e419. doi: 10.1038/tp.2014.58.

2.

Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.

Tarawneh R, Head D, Allison S, Buckles V, Fagan AM, Ladenson JH, Morris JC, Holtzman DM.

JAMA Neurol. 2015 Apr 13. doi: 10.1001/jamaneurol.2015.0202. [Epub ahead of print]

PMID:
25867677
3.

Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42.

Schott JM, Bartlett JW, Fox NC, Barnes J; Alzheimer's Disease Neuroimaging Initiative Investigators.

Ann Neurol. 2010 Dec;68(6):825-34. doi: 10.1002/ana.22315.

PMID:
21181717
4.

Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau.

Dickerson BC, Wolk DA; Alzheimer's Disease Neuroimaging Initiative.

Front Aging Neurosci. 2013 Oct 11;5:55. doi: 10.3389/fnagi.2013.00055. eCollection 2013.

5.

Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls.

Barnes J, Carmichael OT, Leung KK, Schwarz C, Ridgway GR, Bartlett JW, Malone IB, Schott JM, Rossor MN, Biessels GJ, DeCarli C, Fox NC; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2013 Aug;34(8):1996-2002. doi: 10.1016/j.neurobiolaging.2013.02.003. Epub 2013 Mar 21.

6.

The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.

Dowling NM, Johnson SC, Gleason CE, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2015 Jan 15;105:357-68. doi: 10.1016/j.neuroimage.2014.10.050. Epub 2014 Oct 29.

PMID:
25450107
7.

Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease.

Henneman WJ, Vrenken H, Barnes J, Sluimer IC, Verwey NA, Blankenstein MA, Klein M, Fox NC, Scheltens P, Barkhof F, van der Flier WM.

Neurology. 2009 Sep 22;73(12):935-40. doi: 10.1212/WNL.0b013e3181b879ac.

8.

A data-driven model of biomarker changes in sporadic Alzheimer's disease.

Young AL, Oxtoby NP, Daga P, Cash DM, Fox NC, Ourselin S, Schott JM, Alexander DC; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2014 Sep;137(Pt 9):2564-77. doi: 10.1093/brain/awu176. Epub 2014 Jul 9.

9.

The role of clusterin in amyloid-β-associated neurodegeneration.

Desikan RS, Thompson WK, Holland D, Hess CP, Brewer JB, Zetterberg H, Blennow K, Andreassen OA, McEvoy LK, Hyman BT, Dale AM; Alzheimer’s Disease Neuroimaging Initiative Group.

JAMA Neurol. 2014 Feb;71(2):180-7. doi: 10.1001/jamaneurol.2013.4560.

10.

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 Sep;9(5):e111-94. doi: 10.1016/j.jalz.2013.05.1769. Epub 2013 Aug 7. Review.

11.

Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.

Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van der Flier WM, Scheltens P.

Neurobiol Aging. 2010 May;31(5):758-64. doi: 10.1016/j.neurobiolaging.2008.06.016. Epub 2008 Aug 8.

PMID:
18692273
12.

The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease.

Hohman TJ, Bell SP, Jefferson AL; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2015 May 1;72(5):520-9. doi: 10.1001/jamaneurol.2014.4761.

PMID:
25751166
13.

Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease.

Ott BR, Cohen RA, Gongvatana A, Okonkwo OC, Johanson CE, Stopa EG, Donahue JE, Silverberg GD, Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2010;20(2):647-57. doi: 10.3233/JAD-2010-1406.

14.

MRI and CSF studies in the early diagnosis of Alzheimer's disease.

de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H.

J Intern Med. 2004 Sep;256(3):205-23.

PMID:
15324364
15.

3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects.

Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, Cummings JL, Toga AW, Trojanowski JQ, Shaw LM, Jack CR Jr, Petersen RC, Aisen PS, Jagust WJ, Koeppe RA, Mathis CA, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2010 Aug;31(8):1284-303. doi: 10.1016/j.neurobiolaging.2010.05.003. Epub 2010 Jun 11.

16.

Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data.

Tosun D, Schuff N, Shaw LM, Trojanowski JQ, Weiner MW; Alzheimer's Disease NeuroImaging Initiative.

J Alzheimers Dis. 2011;26 Suppl 3:77-90. doi: 10.3233/JAD-2011-0006.

PMID:
21971452
17.

Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.

Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2010 Aug;31(8):1340-54. doi: 10.1016/j.neurobiolaging.2010.04.030. Epub 2010 Jun 8.

18.

Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls.

Chou YY, Leporé N, Avedissian C, Madsen SK, Parikshak N, Hua X, Shaw LM, Trojanowski JQ, Weiner MW, Toga AW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2009 Jun;46(2):394-410. doi: 10.1016/j.neuroimage.2009.02.015. Epub 2009 Feb 21.

19.

Injury markers predict time to dementia in subjects with MCI and amyloid pathology.

van Rossum IA, Vos SJ, Burns L, Knol DL, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, L'italien G, van der Flier WM, Teunissen CE, Blennow K, Barkhof F, Rueckert D, Wolz R, Verhey F, Visser PJ.

Neurology. 2012 Oct 23;79(17):1809-16. doi: 10.1212/WNL.0b013e3182704056. Epub 2012 Sep 26.

20.

CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease.

Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Brewer JB, Dale AM; Alzheimer's Disease Neuroimaging Initiative.

J Neurosci. 2010 Feb 10;30(6):2088-101. doi: 10.1523/JNEUROSCI.3785-09.2010.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk